Dr. Peter Schmid
Professor of Cancer Medicine and Center Lead, Barts Cancer Institute
Replay available
ALX Oncology Holdings Inc. (ALXO) Q3 2025 Earnings Call
ALX Oncology Holdings Inc. (NASDAQ: ALXO) Q3 2025 earnings conference call, held 2025-11-07. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Sam Sutzke
Analyst, LifeSci Capital
Jason Letman
Host; President & CEO
Barb Quinkey
Chief Medical Officer
Daniel Brander
Analyst, Cantor Fitzgerald
Roger Song
Analyst, Jefferies
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Alx Oncology Holdings Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:05.138 Welcome to the ALX Oncology Third Quarter 2025 Financial Results Conference 00:00:05.138 -- 00:00:06.861 Call-In Webcast. 00:00:06.861 -- 00:00:10.125 At this time, all participants are in a listen-only mode. 00:00:10.125 -- 00:00:13.250 A question and answer session will follow the formal presentation. 00:00:13.250 -- 00:00:18.177 If anyone should require operator assistance during the conference, please press star 00:00:18.177 -- 00:00:22.723 zero on your telephone keypad. Please note this conference is being recorded. 00:00:22.723 -- 00:00:27.230 I would now like to turn the conference over to your host, Jason Letman. 00:00:27.230 -- 00:00:29.849 Please go ahead, sir. 00:00:29.849 -- 00:00:33.734 Thanks everyone, and welcome to our Q3 2025 00:00:33.734 -- 00:00:35.136 results. 00:00:35.136 -- 00:00:38.961 I appreciate everybody spending some time with us this morning, and I'm looking forward 00:00:38.961 -- 00:00:44.569 to this update. On slide two here, before we start our presentation of housekeeping, 00:00:44.569 -- 00:00:49.435 here are our forward-looking statements for your review. 00:00:49.435 -- 00:00:54.222 So on the next slide, slide three here, here is the agenda and our plan for today. 00:00:54.222 -- 00:00:58.803 We're going to be providing an update on our key accomplishments in the third quarter 00:00:58.803 -- 00:01:00.505 of 2025. 00:01:00.505 -- 00:01:05.090 Most notably, we are very excited to share with you the data set that will be presented 00:01:05.090 -- 00:01:10.335 at CITSE this weekend from a pre-planned analysis of our Aspen 06 00:01:10.335 -- 00:01:15.761 trial that showed CD47 expression as a key predictive biomarker 00:01:15.761 -- 00:01:21.347 for increasing durable clinical response with avorpace...